Sartorius Stedim Biotech : First-quarter results of Sartorius Stedim Biotech
Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent A good 23 percentage points of growth contributed by the coronavirus pandemic Accelerated expansion of production capacities in all regions on track as planned Sartorius Stedim Biotech, a leading partner of the biopharma industry, had an exceptionally strong start to fiscal 2021 and grew substantially in order intake 1, sales revenue and earnings. This was fueled by strong fundamental growth, addit...
Source: marketscreener.com